Navigation Links
Lilly and MacroGenics Announce Licensing and Collaboration Agreement
Date:10/18/2007

in diabetes care, to develop teplizumab in multiple T-cell-mediated autoimmune diseases and to advance the molecule toward regulatory submission for recent-onset type 1 diabetes," stated Dr. Scott Koenig, president and CEO of MacroGenics. "We also look forward to working with Lilly to develop next generation CD3 product candidates to potentially treat a variety of autoimmune diseases, such as psoriasis and rheumatoid arthritis."

About Teplizumab

Teplizumab, also called MGA031, is a humanized, non-Fc receptor binding, anti-CD3 monoclonal antibody. Teplizumab binds to an epitope of the CD3- epsilon chain expressed on mature T lymphocytes and, by doing so, may modulate the pathological immunologic responses underlying multiple autoimmune diseases. Specifically, teplizumab may inhibit unwanted effector T cells and enhances beneficial regulatory T cell functions, thus promoting immune tolerance.

About the PROTEGE Trial

The PROTEGE trial, a global, pivotal Phase II/III clinical trial study, is evaluating the safety and efficacy of three teplizumab dosing regimens administered at the start of the study and again at six months in individuals with recent-onset type 1 diabetes ages 8 to 35 who are up to 12 weeks from their diagnosis.

Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. Researchers believe teplizumab may control the T lymphocytes that mediate destruction of the insulin-producing beta cells of the islets of the pancreas. In doing so, they believe teplizumab may have the ability to preserve and protect the remaining beta cells of the pancreas.

Additional information regarding the PROTEGE trial is available online at http://www.protegediabetes.org.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Animal insulin product to be discontinued by drug major Eli Lilly
2. Did Eli Lilly Turn Wily With Regard to Their Best-selling Schizophrenia Drug?
3. Eli Lilly Releases Digital Insulin Pen
4. OHSU Researchers Announce New Discovery
5. PM announces a new health care order for India
6. Partnership Between Diabetes India And Elsevier Announced
7. US Politicians Urge Movie Moghuls To Add Anti-Smoking Announcements
8. Ramdoss Announces Introduction of RCH-II
9. Britain Announces Third Transfusion Related Mad Cow Case
10. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
11. Tibet Announces the Dalai Lama’s Tour of South Americ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... According to a June 11, 2013 ABC News article, ... information surfaces about the negative effects of sun on ... one’s skin care routine, as the sun's rays ... , “I agree with the article's suggestions for the best ... of Epione Beverly Hills. “Apply a minimum of SPF 30, ...
(Date:6/17/2013)... Harvard Stem Cell Institute (HSCI) researchers have identified in ... to regulate embryonic stem cell self-renewal, beginning a creative ... , The gene, SALL4, gives stem cells their ability ... mature cells. Typically, cells only express SALL4 during embryonic ... cases of acute myeloid leukemia and 10 to 30 ...
(Date:6/17/2013)... childhood obesity, researchers at the Johns Hopkins Bloomberg ... are important. A systematic review of childhood obesity ... incorporate schools and focus on both diet and ... in children. The results of the study appear ... "In measuring the effectiveness of community-based programs that ...
(Date:6/17/2013)... pyrvinium pamoate inhibits aggressive forms of prostate cancer that ... conducted in an animal model. The results will be ... in San Francisco. , "Our novel prostate cancer drug ... lead author Jeremy Jones, PhD, assistant professor of molecular ... Duarte, CA. "Thus, it has the potential to treat ...
(Date:6/17/2013)... Reliable services of Link to Pay have been offered to ... can fix payment processing. , Schools and colleges have a ... fees from students and processing them may be a herculean ... cases, colleges and universities are looking for some smart solutions ... efficiently without any complications. , At the same time, parents ...
Breaking Medicine News(10 mins):Health News:Skin Care – Answers to Your Sunscreen Questions 2Health News:A new target for cancer drug development 2Health News:Community-based programs may help prevent childhood obesity 2Health News:New medication treats drug-resistant prostate cancer in the laboratory 2Health News:PayCanada Offers Link to Pay Services to its Customers 2
... Legislature,took an important step to help combat the rise ... according to the Michigan Dermatological Society,(MDS). , ... Frank Accavitti (D-Eastpointe), regulates,tanning salons by specifically requiring onsite ... tanning facilities listing potential health,consequences, and a signed informed ...
... company, explains the repercussions and risks of waiting to file for SSDI. ... ... the mistake of waiting too long to apply for Social Security disability ... people in the Social Security Disability Insurance (SSDI) process each ...
... With everyone mindful of,budgets and spending this holiday ... routine perfume or socks and to give gifts that ... too. Finding special gifts for loved ones with,asthma ... and allergy friendly(TM),Certification Program is helping holiday shoppers all ...
... Dec. 11 The following is a statement from Peter ... United States: , , The ... decline in underage drinking. The study,s authors point out that ... of alcohol by those under the legal drinking age. The ...
... Million Patient Pavilion , , CAMDEN, ... filled lobby as visitors gather in the coffee shop sipping lattes ... is the new patient Pavilion at Cooper University Hospital. Cooper celebrated ... a spectacular "Grand Lighting" of the Pavilion. , ...
... 11 Bioenergy Life Science -- The Ribose,Company ... Solutions, LLC, to market,Bioenergy D-Ribose(TM) in the Eastern ... to stimulate the synthesis of adenosine,triphosphate (ATP) -- ... "Collaborating with Xsto Solutions will ...
Cached Medicine News:Health News:Dermatologists Applaud Passage of Tanning Salon Regulation 2Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 2Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 3Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 4Health News:Spend Wisely This Holiday, Find Gifts That Are Good Fun and Good For You 2Health News:Spend Wisely This Holiday, Find Gifts That Are Good Fun and Good For You 3Health News:Cooper Opens Doors to New Era in Healthcare 2Health News:Cooper Opens Doors to New Era in Healthcare 3Health News:Bioenergy Life Science Retains Xsto Solutions to Market D-Ribose 2
(Date:6/17/2013)... TORONTO , June 17, 2013  Generex ... it entered into a securities purchase agreement with certain ... agreed to purchase in a private placement an aggregate ... Series E 9% Convertible Preferred Stock ("convertible preferred stock") ... 100% of the shares of its common stock issuable ...
(Date:6/17/2013)... -- Franciscan St. Francis Health Cancer Center today ... Indiana to use a new drug to treat ... Xofigo ®, a radiopharmaceutical used in patients with late-stage, ... was approved for use by the U.S. Food and Drug ... it may become castration-resistant, which has become resistant to medical ...
(Date:6/17/2013)... OSAKA, Japan , June 17, 2013 ... Takeda Pharmaceuticals U.S.A. , Inc. today ... KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and ... the United States (U.S.). These ... Administration (FDA) for the treatment of type 2 diabetes ...
Breaking Medicine Technology:Generex Announces $1,225,000 Capital Investment 2Generex Announces $1,225,000 Capital Investment 3Generex Announces $1,225,000 Capital Investment 4Generex Announces $1,225,000 Capital Investment 5New drug proving effective in attacking advanced prostate cancer 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 3Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 4Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 5Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 6Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 7Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 8Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 9
The Solar Radius Chair is a multi-functional and cost effective working environment. It can be used for simple and advanced urodynamic studies as well as for routine gynecology investigations....
... The Sonesta 6202 is the ... with our most popular accessories, ... for a myriad of exam ... (yet quiet) motors allow fast ...
... Model BR2 Bilirubin STAT-Analyzer® provides a rapid, ... in neonates. And because it's so compact ... for virtually any laboratory. The Model BR2 ... the only instrument that measures total and ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: